OptimizeRx Co. (NASDAQ:OPRX - Get Free Report) CEO William J. Febbo bought 20,000 shares of the company's stock in a transaction dated Thursday, December 12th. The stock was bought at an average cost of $5.01 per share, with a total value of $100,200.00. Following the completion of the acquisition, the chief executive officer now owns 601,253 shares in the company, valued at $3,012,277.53. This represents a 3.44 % increase in their position. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink.
OptimizeRx Price Performance
Shares of OPRX stock opened at $5.32 on Tuesday. The company has a current ratio of 3.23, a quick ratio of 3.23 and a debt-to-equity ratio of 0.29. The firm has a market capitalization of $97.99 million, a price-to-earnings ratio of -4.00 and a beta of 1.34. The firm's 50 day moving average is $5.51 and its 200-day moving average is $7.96. OptimizeRx Co. has a 1 year low of $3.78 and a 1 year high of $16.65.
Wall Street Analysts Forecast Growth
OPRX has been the subject of several recent analyst reports. Barclays dropped their price objective on OptimizeRx from $11.00 to $5.00 and set an "equal weight" rating for the company in a research note on Thursday, November 14th. JMP Securities reduced their price target on shares of OptimizeRx from $16.00 to $8.00 and set a "market outperform" rating on the stock in a research report on Thursday, November 14th. William Blair reaffirmed an "outperform" rating on shares of OptimizeRx in a report on Thursday, November 14th. Royal Bank of Canada reduced their target price on OptimizeRx from $14.00 to $7.00 and set an "outperform" rating on the stock in a report on Thursday, November 14th. Finally, Roth Mkm reaffirmed a "buy" rating and set a $16.00 price target (down from $20.00) on shares of OptimizeRx in a report on Thursday, November 14th. One analyst has rated the stock with a hold rating and six have given a buy rating to the stock. According to MarketBeat, OptimizeRx has a consensus rating of "Moderate Buy" and a consensus price target of $10.42.
This Crypto Is Set to Explode in December
From Crypto 101 Media | Ad
It's a groundbreaking opportunity that could be poised for extraordinary gains.
The catalyst behind this surge is a massive new blockchain development…
YES, I WANT THE #1 CRYPTO NOW
Check Out Our Latest Analysis on OPRX
Institutional Inflows and Outflows
A number of hedge funds have recently bought and sold shares of the company. Rice Hall James & Associates LLC raised its position in shares of OptimizeRx by 24.0% during the third quarter. Rice Hall James & Associates LLC now owns 615,441 shares of the company's stock worth $4,751,000 after acquiring an additional 119,306 shares during the last quarter. Janney Montgomery Scott LLC acquired a new stake in OptimizeRx in the third quarter worth about $810,000. First Light Asset Management LLC raised its holdings in OptimizeRx by 5.1% during the 2nd quarter. First Light Asset Management LLC now owns 1,826,961 shares of the company's stock worth $18,270,000 after purchasing an additional 89,377 shares during the last quarter. Bullseye Asset Management LLC raised its holdings in OptimizeRx by 55.6% during the 3rd quarter. Bullseye Asset Management LLC now owns 214,046 shares of the company's stock worth $1,652,000 after purchasing an additional 76,458 shares during the last quarter. Finally, Essex Investment Management Co. LLC lifted its position in OptimizeRx by 42.9% during the 3rd quarter. Essex Investment Management Co. LLC now owns 242,025 shares of the company's stock valued at $1,868,000 after purchasing an additional 72,672 shares during the period. 76.47% of the stock is currently owned by institutional investors.
OptimizeRx Company Profile
(
Get Free Report)
OptimizeRx Corporation, a digital health technology company, enables care-focused engagement between life sciences organizations, healthcare providers, and patients at critical junctures throughout the patient care journey. It offers various tech-enabled marketing solutions through its Artificial Intelligence-generated Dynamic Audience and Activation Platform, which enables customers to execute traditional marketing campaigns on its proprietary digital point-of-care network, as well as dynamic marketing campaigns that optimize audiences in real time to increase the value of treatment information for healthcare professionals and patients in response to clinical care events.
Featured Stories
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. This story was reviewed by InsiderTrades.com's editorial team prior to publication. Please send any questions or comments about this story to [email protected].
